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Abstract
Cell-penetrating peptides (CPPs), containing arginine (R), 6-aminohexanoic acid (X), and/or β-
alanine (B) conjugated to phosphorodiamidate morpholino oligomers (PMOs), enhance their delivery
in cell culture. In this study, the potency, functional biodistribution, and toxicity of these conjugates
were evaluated in vivo, in EGFP-654 transgenic mice that ubiquitously express the aberrantly spliced
EGFP-654 pre-mRNA reporter. Correct splicing and enhanced green fluorescence protein (EGFP)
upregulation serve as a positive readout for peptide-PMO (PPMO) entry into cells and access to
EGFP-654 pre-mRNA in the nucleus. Intraperitoneal injections of a series of PPMOs, A-N (12 mg/
kg), administered once a day for four successive days resulted in splicing correction in numerous
tissues. PPMO-B was highly potent in the heart, diaphragm, and quadriceps, which are key muscles
in the treatment of Duchenne muscular dystrophy. We therefore investigated PPMO M23D-B,
designed to force skipping of stop-codon containing dystrophin exon 23, in an mdx mouse model of
the disease. Systemic delivery of M23D-B yielded persistent exon 23 skipping, yielding high and
sustained dystrophin protein expression in body-wide muscles, including cardiac muscle, without
detectable toxicity. The rescued dystrophin reduced serum creatinine kinase to near-wild-type levels,
indicating improvement in muscle integrity. This is the first report of oligonucleotide-mediated exon
skipping and dystrophin protein induction in the heart of treated animals.
Introduction
In order to enhance the efficacy of antisense oligonucleotides as therapeutic agents, numerous
chemical modifications have been introduced to their bases, backbones, and internucleotide
linkages.1 One such modification, phosphorodiamidate morpholino oligomers (PMOs),2,3
bind their RNA targets with high affinity and specificity, and are highly resistant to nucleolytic
degradation; however, their systemic distribution and functionality were found to be modest
in mouse model systems.4 Subsequently, conjugates of PMOs with arginine-rich cell-
penetrating peptides (CPPs), termed peptide-PMOs (PPMOs), were found to possess enhanced
potency in vitro.5–8 In particular, serum and intracellular stability of peptides was increased,
endosomal trapping was reduced, and nuclear uptake was enhanced by the introduction of non-
α amino acids, namely, 6-aminohexanoic acid (X) and β-alanine (B), into the oligoarginine
(R8) peptides.9–12
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In this study, a series of PPMOs carrying CPPs consisting of R8 residues and a variable number
of X and/or B residues (termed A through N, Table 1) was designed. The series was first
evaluated in EGFP-654 transgenic mice, which ubiquitously express an enhanced green
fluorescence protein (EGFP) pre-mRNA interrupted by an aberrantly spliced human β-globin
IVS2-654 intron. The EGFP upregulation serves as a positive readout for the ability of PPMOs
to enter cells and correct aberrant splicing of the EGFP-654 pre-mRNA in the nucleus4 (Figure
1a). After delivery through intraperitoneal (IP) injection, all PPMOs exhibited a broad tissue
distribution and corrected the aberrant splicing in EGFP-654 mice to varying degrees.
One of the conjugates, PPMO-B, was very effective in the heart, diaphragm, and quadriceps,
the target muscles for treatment of Duchenne muscular dystrophy (DMD), a severe progressive
muscle wasting disorder.13 This work focused on the use of PPMO-B in the treatment of DMD
in an mdx mouse model of the disease. We found that systemic delivery of a PPMO-B targeted
to exon 23 of the dystrophin gene (M23D-B) induced high and sustained dystrophin protein
expression in body-wide muscles in treated mdx mice. This led to improved cardiac histology
and a dramatic drop in serum creatinine kinase (CK), a hallmark of improvement in muscle
integrity.
Results
Functional biodistribution of PPMO-654 conjugates in EGFP-654 mice
In order to evaluate the in vivo potency and functional biodistribution of PPMOs, EGFP-654
mice were injected IP once a day for 4 days at 12 mg/kg/day with PPMO-654 conjugates (A
through N, Table 1), targeted to the aberrant 5′-splice site in EGFP-654 pre-mRNA (Figure
1a). One day after the last injection, the mice were killed, and total RNA was isolated from
tissues and analyzed using reverse transcriptase-PCR (RT-PCR). The results show that all the
PPMO-654 conjugates exhibited broad tissue-wide distribution, with significant splicing
correction in most tissues (Figure 1b) (but not in brain and bone marrow; Supplementary Figure
1a), which was substantially higher than that achieved with higher doses of unconjugated
PMOs.4
The number and position of 6-aminohexanoic acid (X) and/or β-alanine (B) residues inserted
in the oligoarginine (R8) in the CPPs significantly affected the potency and functional
biodistribution of the PPMOs. PPMO-A, containing 8 arginines, 1 X residue and 1 B residue
was very effective in modifying EGFP-654 pre-mRNA splicing in liver (∼63%), but was much
less effective in several other tissues including the quadriceps and the heart (Figure 1b). In
contrast, PPMO-B was the most effective in the quadriceps (100%) and the heart (59%), but
its efficacy in the liver was similar to that of PPMO-A. PPMO-J was highly effective in the
kidney (100%) and quadriceps (100%) but not in the heart (21%). Surprisingly, all the PPMOs
corrected the EGFP-654 splicing in diaphragm 100%. Overall, the differences in the functional
biodistribution of PMOs conjugated with a family of closely related peptides are striking, and
more structure-activity studies are needed to elucidate the causes and mechanisms of these
differences.
We noticed that PPMO-B is the most potent in all muscle tissues, especially the heart. PPMO-
B did not produce toxicity in mice at the doses tested (Figure 1c and Supplementary Figure
1b), and the data in Figure 2a and b show a clear dose–response in the heart and quadriceps,
while in the diaphragm, even at the low dose of 3 mg/kg, 100% of correctly spliced EGFP
mRNA was produced. Therefore, PPMO-B represents a promising candidate for the treatment
of DMD. The strategy developed in our laboratory14,15 is to induce in-frame skipping of an
offending exon which causes a premature termination codon, restoring production of functional
dystrophin protein (Supplementary Figure 2).
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In order to determine the persistence of PPMO-B activity, EGFP-654 mice were injected
intravenously (IV) at 12 mg/kg/day for 4 days, and killed up to 12 weeks after the last injection
(Figure 2c); IV administration of PPMO-B was more efficient than IP and subcutaneous routes,
especially in the heart (Supplementary Figure 3). The splicing correction in the heart reached
90% at 1 day after the last injection and then gradually decreased, but was still detectable
(∼10%) at 6 weeks. In the diaphragm, 100% correctly spliced EGFP mRNA was detectable
up to 2–3 weeks after the last injection, decreasing to 10–40% at 12 weeks. Impressively,
PPMO-B exhibited 100% splicing correction in the quadriceps up to 12 weeks after the last
injection.
The expression of EGFP was also followed-up in live animals using the Xenogen IVIS 100
imaging system (Figure 2d). The EGFP signal was detectable in the abdominal fascia and
quadriceps from 1 week after the last injection, and increased for up to 5 weeks without any
decrease in fluorescence intensity at week 8. A PPMO targeted to mouse dystrophin with three
mismatches (PPMO mis-23D), used as a negative control, did not upregulate EGFP.
Skipping of dystrophin exon 23 in mdx mice by PPMO M23D-B
The phenotype of the mdx mouse is caused by a premature termination codon in exon 23 of
the dystrophin gene (Supplementary Figure 2), which prevents translation of dystrophin
protein. Oligonucleotide-induced skipping of exon 23 during splicing of dystrophin pre-mRNA
restores the reading frame in the spliced mRNA, resulting in the production of partially
functional truncated dystrophin protein in the skeletal muscles of mdx mice.16–18 Recently,
the systemically delivered unconjugated morpholino oligonucleotide, PMO M23D, targeted
to a donor splice site of mouse dystrophin intron 23, was found to be effective in skeletal
muscles but, importantly, not in the heart.19,20 Given that, as described earlier in the text,
PPMO-B was highly efficient and persistent in splicing correction in the heart, diaphragm, and
quadriceps in EGFP-654 mice, we synthesized the PPMO M23D-B conjugate for treating
mdx mice.
The mdx mice were injected IV once every day for 4 days with M23D-B at 12 mg/kg/day
(Figure 3). Muscle tissues were collected and analyzed at the indicated time points for exon
skipping, by nested RT-PCR of dystrophin mRNA. In the heart, the exon 23–skipped
dystrophin mRNA reached 70% at 1 day after the last injection and decreased to 50 and 20%
at 2 and 7 weeks, respectively; at 9 weeks after the last injection, exon 23 skipping was still
detectable. In the diaphragm and quadriceps, M23D-B induced almost complete exon 23
skipping, and this remained essentially unchanged up to 9 weeks after the last injection. Similar
activity was detected in all the other skeletal muscles (Supplementary Figure 4). No exon 23–
skipped transcript was observed in saline or mismatched oligo-treated mdx mice or in wild-
type C57BL6 mice (data not shown).
Analysis of total protein from M23D-B-treated mice by in-gel immunostaining with anti-
dystrophin antibody (Figure 4a) showed that, in the heart, the dystrophin levels reached ∼30%
of wild-type at 2–3 weeks and remained at ∼15% up to 7 weeks after the last injection. This is
the first report of oligonucleotide-mediated exon skipping and dystrophin protein induction in
the heart. In the diaphragm and quadriceps, significant dystrophin production, 40–50% of wild
type, was achieved and maintained for up to 17 weeks after the last injection (Figure 4a). The
multiple dystrophin bands detected in samples from wild-type and treated mdx mice were
naturally occurring variants or synthetic intermediates of dystrophin.21 These results clearly
confirm that the persistent skipping of exon 23 induced by M23D-B resulted in robust
translation of dystrophin protein, which persisted for up to 17 weeks after the last injection,
and localized correctly at the periphery of muscle fibers (Figure 4b). As expected, no detectable
dystrophin protein was observed in untreated mdx mice.
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The discrepancy between the level of exon skipping in mRNA (100%) and the level of induced
dystrophin protein (40–50%) relative to wild type suggests that RT-PCR overestimates the
extent of exon-skipped mRNA. This is not surprising, considering that nested PCRs were
required. Note, however, that we used a total of 30 cycles in the PCR, which compares favorably
with published 55 cycle nested PCR protocols.18 It is also possible that the full-length
dystrophin mRNA carrying premature termination codon in exon 23 may be degraded by
nonsense-mediated decay, resulting in overestimation of corrected dystrophin mRNA.
Nevertheless, the important observation is that therapeutically relevant levels22,23 of
dystrophin were produced in all key muscle types: skeletal muscle, diaphragm, and heart.
The sera collected during the experiment were tested for CK, a marker for heart and skeletal
muscle membrane instability.24,25 Figure 5a demonstrates a dramatic reduction in the level
of serum CK from ∼30,000 to <2,000 U/l 1 day after the last injection. Commensurate with
additional increases in dystrophin in subsequent weeks (Figure 4a), serum CK levels were
further reduced to ∼500 U/l. This level was maintained for 11 weeks after the last injection,
and increased only at 17 weeks, the time point at which dystrophin protein was barely detectable
in the heart, and somewhat decreased in the diaphragm and quadriceps. A similar pattern was
observed for circulating levels of aspartate aminotransferase and alanine aminotransferase
(Figure 5b), which are present in a variety of extrahepatic tissues, including cardiac and skeletal
muscles confirming that the restored dystrophin protein improved the integrity of muscle
sarcolemma. Specifically to the heart, cardiac muscle stained with hematoxylin and eosin
showed significant reduction of inflammatory cell infiltration in mdx mice treated with M23D-
B at 3 weeks after the last injection (Figure 5c), suggesting that necrosis in cardiac muscle was
significantly reduced.
Discussion
In this study, we first used EGFP-654 mice to evaluate the potential of peptide-conjugated
PMOs as splice-switching oligonucleotides. This mouse model provides a positive readout for
functional biodistribution data, indicating where the conjugates are functionally active. The
results clearly show that systemically delivered PPMOs corrected EGFP-654 splicing to a high
degree in a number of different tissues, and were essentially nontoxic at the doses used in the
study. Comparison with an unconjugated PMO that was investigated in previous experiments
in the same animal model indicates that the CPPs altered the functional biodistribution of
PPMOs and significantly enhanced their potency and intracellular delivery.4 The effects of the
CPPs are dependent on the number and position of the non-α amino acids, aminohexanoic acid
(X), and/or β-alanine (B) (X and/or B residues). These differences could be attributable to the
stability of the conjugates in serum and cells,11 or to their ability to escape from endosomes/
lysosomes.12
In EGFP-654 mice, PPMO-B delivered by IV injection at 12 mg/kg/day for 4 days was highly
potent in splicing correction in cardiac muscle, diaphragm, and quadriceps, and its activity
persisted in these muscles for at least 2–3 months. Therefore, we applied its equivalent, PPMO
M23D-B, in the treatment of muscular dystrophy in mdx mice. Systemic delivery of M23D-B
induced skipping of exon 23, thereby restoring and sustaining dystrophin protein expression
which localized correctly at the plasma membrane of muscle fibers in body-wide muscles,
including the heart. It is also important to note that the smooth muscles of the digestive tract
are impaired in DMD;26 PPMO-B has an effect on these tissues, e.g., stomach, small intestine,
and colon (Supplementary Figure 1a), and should therefore provide amelioration of related
symptoms in patients.
Induction of exon 23 skipping mediated by M23D-B conjugate was significantly more efficient
than that mediated by the unconjugated PMO.19 More importantly, the M23D-B showed
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induction of exon skipping, production of induced dystrophin protein, and histological
improvement in cardiac muscle, the first such results using an antisense oligonucleotide. Given
that 30% of deaths in DMD patients are caused by cardiomyopathy,27 it is crucial to induce
dystrophin expression in cardiac muscle. Clearly, the expression of dystrophin ameliorated the
sarcolemmal integrity of muscles, leading to dramatic decreases in serum CK, aspartate




The sequences of CPPs are indicated in Table 1. All PPMOs were synthesized and purified as
described by Wu et al.8 and targeted to the aberrant 5′-splice site in the intron of EGFP-654
pre-mRNA. (PPMO-654; 5′-GCT ATT ACC TTA ACC CAG-3′).4 PPMO M23D-B was
targeted to the 5′-splice site of intron 23 (5′-GGC CAA ACC TCG GCT TAC CTG AAA T-3′)
of mouse dystrophin pre-mRNA.28 A mismatched M23D-B (mis-23D-B, 5′-GCG CAA ACC
TCG CGT TAC CGT AAA T-3′) was used as a control. In all EGFP-654 PPMOs, the CPPs
were conjugated at the 5′-end; in M23D-B, peptide B was conjugated at the 3′-end. All PPMOs
were resuspended and diluted in sterile normal saline.
Animal treatment
All experiments involving animals were approved by Institutional Animal Care and Use
Committee at the University of North Carolina. PPMOs were delivered once daily to 7–8-
week-old EGFP-654 or C57BL/10ScSnmdx (mdx; Jackson Laboratory, Bar Harbor, ME) mice
by IP, IV, or subcutaneous injections at the indicated doses for 4 days. The mice were killed
by CO2 inhalation, and the tissues were removed and stored at −80 °C for RNA isolation or
fixed in 4% paraformaldehyde4,29 for EGFP visualization. For immunofluorescence, muscle
tissues from mdx mice were mounted in Tissue-Tek optimal cutting temperature embedding
medium (Sakura, Torrance CA), snap-frozen in isopentane, and stored at –80 °C.
RNA isolation and analysis
Total RNA was isolated from ∼1–5 mg tissue with TRI Reagent (Molecular Research Center,
Cincinnati, OH) as per the manufacturer's protocol. The EGFP mRNA was amplified by RT-
PCR as described earlier,29 except that 1 μl of 0.1 mmol/l of Cy5-deoxycytidine triphosphate
(GE Healthcare, Amersham, UK) was added into the PCR instead of 32P-labeled
deoxyadenosine triphosphate. The dystrophin mRNA was amplified using nested RT-PCR.
Total RNA (400 ng) was subjected to RT-PCR (5′-GTT CAG CTT CAC TCT TTA TCT TCT
GCC-3′, reverse outer primer; 5′-CAA TGT TTC TGG ATG CAG ACT TTG TGG-3′, forward
outer primer) with rTth DNA polymerase (Applied Biosystems, Foster City, CA). Reverse
transcription was at 70 °C for 15 minutes; PCR was at 95 °C for 3 minutes, followed by 8
cycles of 95 °C for 1 minute, 55 °C for 1 minute, and 72 °C for 1 minute. One microliter of
the reaction was then subjected to nested PCR with Platinum Taq DNA polymerase (Invitrogen,
Carlsbad, CA) and labeled with Cy5-deoxycytidine triphosphate (forward inner primer 5′-CAC
ATC TTT GAT GGT GTG AGG-3′; reverse inner primer 5′-CAA CTT CAG CCA TCC ATT
TCT G-3′). The nested PCR was carried out for 22 cycles as described earlier. The RT-PCR
products from EGFP and dystrophin mRNAs were separated on 10% nondenaturing
polyacrylamide gels (Invitrogen) and scanned on Typhoon 9400 Imager (GE Healthcare,
Amersham, UK). The ImageQuant TL (version 2005) analysis software was used for
quantifying the intensity of bands.
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Protein extraction and in-gel immunodetection
Total protein was extracted from muscle samples using the total protein extraction kit
(Millipore, Billerica, MA) as per the manufacturer's protocol, and quantified using the Quick
Start Bradford protein assay kit (Bio-Rad Laboratories, Hercules, CA). Total protein (100 μg)
was loaded onto NuPAGE 3–8% Tris-acetate gels and electrophoresed in 1× NuPAGE Tris–
acetate–SDS running buffer (Invitrogen, Carlsbad, CA). Dystrophin was visualized by in-gel
immunodetection. After electrophoresis, the gel was fixed in 50% isopropanol/5% acetic acid
for 15 minutes, washed in water for 15 minutes, and incubated overnight at room temperature
with NCL-DYS2, a mouse monoclonal antibody against C-terminus of dystrophin
(Novocastra, Newcastle upon Tyne, UK), diluted in StartingBlock (phosphate-buffered saline)
blocking buffer (1:50; Pierce, Rockford, IL). The gel was then washed in PBST (phosphate-
buffered saline and 0.1% Tween-20) three times for 10 minutes each, and incubated for 2 hours
at room temperature with the IRDye 680 goat anti-mouse IgG (LI-COR, Lincoln, NE)
secondary antibody, diluted in StartingBlock (phosphate-buffered saline) blocking buffer
(1:1,000). After three 20-minute washes in PBST and in phosphate-buffered saline overnight,
the gel was scanned and quantitated using Odyssey infrared imaging system (LI-COR).
Dystrophin immunofluorescence and muscle histology
The 8-μm muscle sections were examined for dystrophin expression using NCL-DYS2 mouse
monoclonal antibody and an M.O.M. kit (Vector Laboratories, Burlingame, CA). Briefly, the
sections were incubated with primary antibody at a dilution of 1:20 for 2 hours at room
temperature, followed by incubation with the biotinylated anti-mouse IgG for 1 hour and
fluorescein avidin D cell sorting for 5 minutes. Mounted sections were visualized using a Zeiss
Axio microscope at ×100 magnification. Sections were stained with hematoxylin and eosin for
histological analysis, carried out by Animal Histopathology Core Facility (Lineberger
Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC).
Live animal fluorescence imaging
In vivo fluorescent imaging was performed using Xenogen IVIS 100 (Caliper Life Sciences,
Hopkinton, MA). The mice were anesthetized with 2.5% isoflurane. After hair removal with
depilatory lotion, the mice were placed on the warmed camera box with continuous exposure
to 2.5% isoflurane. Fluorescent images were acquired and analyzed using Live Image 2.2
software.
Clinical biochemistry
Analyses of serum aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen,
creatinine, and CK were performed at the Animal Clinical Laboratory Core Facility (University
of North Carolina) using a Vitro 250 Chemical Analyzer (Ortho-Clinical Diagnostics,
Rochester, NY).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Correction of aberrant splicing in EGFP-654 mice by PPMO-654 conjugates, and the
toxicity of the conjugates
(a) The EGFP-654 mice express a modified EGFP-654 pre-mRNA in which the enhanced
green fluorescence protein (EGFP) coding region (boxes) is interrupted by an aberrantly spliced
human β-globin IVS2-654 intron (line). The aberrantly spliced mRNA retains an intron
fragment (red line), preventing proper translation of EGFP. Blocking the aberrant 5′-splice site
with PPMO-654 (shaded bar) restores the correct splicing, leading to EGFP upregulation. The
EGFP upregulation in mice is observed using a fluorescent live imaging system. (b) Reverse
transcriptase-PCR (RT-PCR) of total RNA from the tissues of PPMO-treated EGFP-654 mice.
The EGFP-654 mice were treated with PPMO-654 conjugates by intraperitoneal injection once
every day for 4 days at 12 mg/kg/day. RNA samples were extracted from the indicated tissues
of the treated mice and analyzed using RT-PCR 1 day after the last injection. The Cy5-labeled
RT-PCR products from aberrantly spliced and correctly spliced EGFP mRNA are shown as
Ab [160 base pairs (bp)] and C (87 bp), respectively. (c) Levels of serum aspartate
aminotransferase and alanine aminotransferase were monitored before the treatment and at 1
day after the last injection of PPMO-654 conjugates. PPMO, peptide-phosphorodiamidate
morpholino oligomer.
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Figure 2. Effective and persistent splicing correction of PPMO-B conjugate in the heart, diaphragm
(diap), and quadriceps (quad) of EGFP-654 mice
(a–b) Dose-dependent splicing correction. EGFP-654 mice were treated with PPMO-B
conjugate at the indicated doses by intravenous (IV) injection once every day for 4 days. (a)
Reverse transcriptase-PCR (RT-PCR) of total RNA and (b) fluorescent images of tissue
sections were analyzed 1 day after the last injection. Samples A and B are from different mice.
(Scale bar = 100 μm). (c–d) Time-dependent splicing correction. The EGFP-654 mice were
injected IV with PPMO-B conjugate at 12 mg/kg/day for 4 days. (c) Total RNA samples from
the heart, diap, and quad were analyzed using RT-PCR at the indicated time points. (d)
Upregulation of enhanced green fluorescence protein (EGFP) expression was monitored using
a fluorescent live imaging system. WT is a mouse that constitutively expresses EGFP. The
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EGFP-654 mice treated with PPMO-B, the control mice treated with PPMO-B at 12 mg/kg,
and untreated mice are shown as B, scr-B, and un, respectively. PPMO, peptide-
phosphorodiamidate morpholino oligomer.
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Figure 3. Persistence of M23D-B-induced exon 23 skipping of dystrophin transcript in the heart,
diaphragm (diap), and quadriceps (quad) of mdx mice after intravenous injection at 12 mg/kg/day
for 4 days
RNA samples were analyzed using nested reverse transcriptase-PCR (RT-PCR) at the indicated
time points. The nested RT-PCR product from the full-length dystrophin transcript is 445 base
pairs (bp), indicated by boxes numbered 21–24. The product from exon 23–skipped mRNA is
232 bp, as indicated by boxes numbered 21, 22, and 24.
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Figure 4. Restoration of dystrophin (Dys) expression in the heart, diaphragm (diap), and
quadriceps (quad) of M23D-B-treated mice after intravenous injections at 12 mg/kg/day for 4 days
(a) In-gel western blot detection of total protein extracted from injected mdx muscles at the
indicated time points. Dys protein was detected by mouse monoclonal antibody against C-
terminus of Dys, followed by IRDye 680 goat anti-mouse immunoglobulin G (IgG) antibody.
The three different Dys bands represent naturally occurring variants or synthetic intermediates
of Dys. (b) Immunofluorescence detection of Dys on frozen muscle sections from the heart,
diap, and quad of treated mdx mice. Sections were immunostained for Dys with NCL-DYS2
and detected using biotinylated anti-mouse IgG and fluorescein avidin. Sections from the heart,
diap, and quad were analyzed 3, 2, and 2 weeks after the last injection, respectively. Muscle
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sections from C57BL and untreated mdx mice were included as positive and negative controls,
respectively. Scale bar, 100 μm.
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Figure 5. Improvement of pathology markers in mdx mice treated intravenously with M23D-B at
12 mg/kg/day for 4 days
(a) Serum creatinine kinase (CK). C57BL (n = 5), treated mdx mice (n = 2 at each time point),
and untreated mdx mice (n = 20). (b) Serum aspartate aminotransferase (AST) and alanine
aminotransferase (ALT). C57BL (n = 3), treated mdx mice (n = 2 at each time point), and
untreated mdx mice (n = 10). All bar graphs represent mean except the bar graphs of serum
CK of C57BL and untreated mdx mice, which represent mean and SEM. (c) Hematoxylin and
eosin staining of cardiac muscle. C57BL at 8 weeks of age, treated mdx at 11 weeks of age (3
weeks after last injection), and untreated mdx at 8 weeks of age. Arrows, inflammatory
infiltrate; Scale bar, 100 μm.
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Table 1
Nomenclature and sequences of CPPs
Name Sequence Abbreviation Length
A RRRRRRRRXB (R)8XB 10
B RXRRBRRXRRBRXB (RXRRBR)2XB 14
C RXRRXRRXRRBRXB (RXR)3RBRXB 14
D RBRBRBRBRBRXRBRXB (RB)5RXRBRXB 17
E RBRBRBRXRBRBRBRXX (RB)3RX(RB)3RXX 17
F XRBRBRBRXRBRBRBRX X(RB)3RX(RB)3RX 17
G RBRXRBRXRBRXRBRXB (RBRX)4B 17
H RBRBRBRBRXRXRXRXB (RB)4(RX)4B 17
I RXRBRBRXRBRBRBRXX RX(RB)2RX(RB)3RXX 17
J rXrrXrrXrrXrXB (rXr)4XB 14
K RXRRXRRXRRXRXB (RXR)4XB 14
L RBRBRBRBRBRBRBRBB (RB)8B 17
M RBRBRBRBRBRBRBRXB (RB)7RXB 17
N RBRBRBRBRBRBRBRBB (RB)8B 17
Abbreviation: CPP, cell-penetrating peptide.
B, β-alanine; r, D-arginine; R, L-arginine; X, 6-aminohexanoic acid.
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